Use eCOA to start your trial the right way


Delivering vaccine trials can be a huge challenge, logistically, financially and time-wise. The nature of these studies means time pressures are inherent, focusing on getting the first patient in (FPI) or meeting database lock timescales. This is intensified further for seasonal vaccines or those targeting epidemics. You may be tempted to opt for a paper-based study to get started quickly but, before you do, think about a digital solution for a moment.

With ERT’s eCOA vaccine solution you can get started quickly, easing time pressure. An eCOA-based trial is much easier to manage and easier to engage participants within the vaccine trial. More importantly, eCOA delivers faster, higher-quality trials.


1. ERT. (2018). Merck Research Laboratories Reduces Standard Deviation with Electronic Pro. Retrieved from https://www.ert.com/. 2. McKenzie, S., Paty, J. and Grogan, D. et al. (2004). Proving the eDiary dividend. Applied Clinical Trials, 13(6): 54–68.


How ERT eCOA does it faster…


We understand you want to hit the ground running, which is why the ERT eCOA Vaccines Platform is the most efficient solution for your vaccines trial.


INCREASE DATA QUALITY AND SPEED

Vaccine studies involve large amounts of patients across different countries, which generate huge amounts of data. Our eCOA solution is quick to deploy, minimizes incomplete or incorrect data and there is no need for manual data entry. The data is also more secure and can be linked to other data sources, making real-time analysis easier and quicker.


EASY PARTICIPANT ENROLLMENT

Site staff use the intuitive ERT portal to enroll new participants. This digital process simplifies enrollment and removes the need for on-site paper diary storage. Site staff will also monitor patient diary card compliance and completion in real time.


LOW-RISK TRANSITION TO eCOA

If you’re moving from paper to eCOA, vaccine trials can be delivered more quickly and easily while accommodating the needs of patients, site staff and stakeholders.


TAILORED STUDIES,
SET UP QUICKLY

Vaccine studies require multiple languages and variations of questions. In ERT’s configurable Vaccines Platform, the set of standards for participant questionnaires is entered, tested and pre-validated. This enables swift, cost-effective deployment of an eCOA solution to first-patient-in.


To understand how ERT’s eCOA vaccines solution supports
your vaccines trial take a look at the videos below.


 


WHY eCOA IS THE WAY TO GO.

eCOA delivers high-quality data which meets FDA ALCOA standards i.e. Attributable to the person, Legible, Contemporaneous (filled in at the right time), Original and Accurate. For case studies and additional information about the benefits of using eCOA click the links below




Vaccine developer achieves cost effective transition to electronic data capture

Top ten pharma company adopts electronic data capture platform to improve data quality.


Paper Vs electronic data capture

Explore the benefits of electronic Patient Reported Outcomes (ePRO) data in clinical trials.


Improving patient data capture in vaccine studies

How a reusable eCOA platform can benefit sponsors, sites, and patients.



7 reasons to implement electronic data collection in your next clinical trial

Your guide to improving study performance and timelines.




REQUEST A FREE DEMO

To reduce trial complexity, know and control your costs from the start and deliver a fast trial, there is only one platform. ERT eCOA for Vaccines.